51
|
Engel-Riedel W, Schneller F, Wolf M, Schuette W, Lowe J, Mattson P, Gargano M, Patchen M, Huhn R, Braun A. Imprime Pgg, a Novel Immune Modulator, in the 1St-Line Treatment of Stage Iv Nsclc: Results from a Randomized, Controlled, Multicenter Phase 2 Study. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu438.35] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
52
|
Braun A, Kokkinos D, Briesen H. Modellierung des Einflusses von Scherbelastung auf Mikroalgen-Populationen. CHEM-ING-TECH 2014. [DOI: 10.1002/cite.201450371] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
|
53
|
Braun A, Briesen H. Flockulation von Hefezellen. CHEM-ING-TECH 2014. [DOI: 10.1002/cite.201450457] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
54
|
Spigel D, Hirsch F, De Boer R, Natale R, Crawford J, Weiss G, Glaspy J, Feng A, Braun A, Jain R. A Phase 2, Randomized, Double-Blind, Multicenter Trial of Denosumab in Combination with Chemotherapy As First-Line Treatment of Metastatic Non-Small Cell Lung Cancer. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu349.109] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
55
|
Patchen M, Gargano M, Grady M, Lowe J, Huhn R, Braun A. A Phase 3 Open-Label, Randomized, Multicenter Study of Imprime Pgg in Combination with Cetuximab in Patients with Kras Wild Type Metastatic Colorectal Cancer. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu342.26] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
56
|
Schneller F, Thomas M, Sadjadian P, Kollmeier J, Bose N, Patchen M, Lowe J, Mattson P, Gargano M, Huhn R, Braun A. Chemoimmunotherapy of Advanced Non-Small Cell Lung Cancer (Nsclc) with Imprime Pgg (Ipgg) in Combination with Cetuximab, Carboplatin and Paclitaxel–Analysis of Secondary Endpoints of a Multicenter, Randomized Phase 2 Trial. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu342.24] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
57
|
Terpos E, Raje N, Durie B, Garcia-Sanz R, Shimizu K, Willenbacher W, Zhu L, Braun A, Jain R, Palumbo A. Comparison of Denosumab Vs Zoledronic Acid for Treatment of Bone Disease in Adults with Newly Diagnosed Multiple Myeloma: a Randomized, Double-Blind, Multinational Phase 3 Trial. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu356.72] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
58
|
Block G, Egbuna O, Zeig S, Pergola P, Singh B, Braun A, Yu Y, Sohn W, Padhi D. Safety of Denosumab (Dmab) in Patients (Pts) with Stage 4 or Stage 5D Chronic Kidney Disease (Ckd). Ann Oncol 2014. [DOI: 10.1093/annonc/mdu356.33] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
59
|
Danov O, Jimenez Delgado SM, Drake H, Schindler S, Pfennig O, Förster C, Braun A, Sewald K. Species comparison of interleukin-13 induced airway hyperreactivity in precision-cut lung slices. Pneumologie 2014. [DOI: 10.1055/s-0034-1376770] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
60
|
Auweter H, Braun A, Mayer U, Schmid D. Dynamics of Energy Transfer by Singlet Excitons in Naphthalene Crystals as Studied by Time-Resolved Spectroscopy. ACTA ACUST UNITED AC 2014. [DOI: 10.1515/zna-1979-0615] [Citation(s) in RCA: 33] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Abstract
The time-resolved sensitized fluorescence of anthracene-doped naphthalene crystals following picosecond-pulse excitation was investigated experimentally as a function of dopant concentration and temperature. The influence of the excitation intensity on the decay of pure naphthalene crystals is studied and yields an almost temperature-independent annihilation constant, yss ≈ 4 x 10-11 cm3 s-1 . The analysis of the time-resolved host and guest fluorescence shows that the energy transfer rate, kHG > changes its functional form with the guest concentration. The temperature dependence of the energy transfer rate is explained tentatively in terms of phonon relaxation and phonon promotion processes.
Collapse
Affiliation(s)
- H. Auweter
- Physikalisches Institut, Teil 3, Universität Stuttgart
- Present address: Department of Chemistry, University of California, Berkeley, California 94720, USA
| | - A. Braun
- Physikalisches Institut, Teil 3, Universität Stuttgart
| | - U. Mayer
- Physikalisches Institut, Teil 3, Universität Stuttgart
| | - D. Schmid
- Physikalisches Institut, Teil 3, Universität Stuttgart
| |
Collapse
|
61
|
Kurnatowska I, Grzelak P, Masajtis-Zagajewska A, Kaczmarska M, Stefa czyk L, Vermeer C, Maresz K, Nowicki M, Patel L, Bernard LM, Elder GJ, Leonardis D, Mallamaci F, Tripepi G, D'Arrigo G, Postorino M, Enia G, Caridi G, Marino F, Parlongo G, Zoccali C, Genovese F, Boor P, Papasotiriou M, Leeming DJ, Karsdal MA, Floege J, Delmas-Frenette C, Troyanov S, Awadalla P, Devuyst O, Madore F, Jensen JM, Mose FH, Kulik AEO, Bech JN, Fenton RA, Pedersen EB, Lucisano S, Villari A, Benedetto F, Pettinato G, Cernaro V, Lupica R, Trimboli D, Costantino G, Santoro D, Buemi M, Carmone C, Robben JH, Hadchouel J, Rongen G, Deinum J, Navis GJ, Wetzels JF, Deen PM, Block G, Fishbane S, Shemesh S, Sharma A, Wolf M, Chertow G, Gracia M, Arroyo D, Betriu A, Valdivielso JM, Fernandez E, Cantaluppi V, Medica D, Quercia AD, Dellepiane S, Gai M, Leonardi G, Guarena C, Migliori M, Panichi V, Biancone L, Camussi G, Covic A, Ketteler M, Rastogi A, Spinowitz B, Sprague SM, Botha J, Rakov V, Floege J, Floege J, Ketteler M, Rastogi A, Spinowitz B, Sprague SM, Botha J, Braunhofer P, Covic A, Kaku Y, Ookawara S, Miyazawa H, Ito K, Ueda Y, Hirai K, Hoshino T, Mori H, Nabata A, Yoshida I, Tabei K, El-Shahawy M, Cotton J, Kaupke J, Wooldridge TD, Weiswasser M, Smith WT, Covic A, Ketteler M, Rastogi A, Spinowitz B, Sprague SM, Botha J, Braunhofer P, Floege J, Hanowski T, Jager K, Rong S, Lesch T, Knofel F, Kielstein H, McQuarrie EP, Mark PB, Freel EM, Taylor A, Jardine AG, Wang CL, Du Y, Nan L, :Hess K, Savvaidis A, Lysaja K, Dimkovic N, Floege J, Marx N, Schlieper G, Skrunes R, Larsen KK, Svarstad E, Tondel C, Singh B, Ash SR, Lavin PT, Yang A, Rasmussen HS, Block GA, Egbuna O, Zeig S, Pergola PE, Singh B, Braun A, Yu Y, Sohn W, Padhi D, Block G, Chertow G, Fishbane S, Rodriguez M, Chen M, Shemesh S, Sharma A, Wolf M, Delgado G, Kleber ME, Grammer TB, Kraemer BK, Maerz W, Scharnagl H, Ichii M, Ishimura E, Shima H, Ohno Y, Tsuda A, Nakatani S, Ochi A, Mori K, Inaba M, Filiopoulos V, Manolios N, Hadjiyannakos D, Arvanitis D, Karatzas I, Vlassopoulos D, Floege J, Botha J, Chong E, Sprague SM, Cosmai L, Porta C, Foramitti M, Masini C, Sabbatini R, Malberti F, Elewa U, Nastou D, Fernandez B, Egido J, Ortiz A, Hara S, Tanaka K, Kushiyama A, Sakai K, Sawa N, Hoshino J, Ubara Y, Takaichi K, Bouquegneau A, Vidal-Petiot E, Vrtovsnik F, Cavalier E, Krzesinski JM, Flamant M, Delanaye P, Kilis-Pstrusinska K, Prus-Wojtowicz E, Szepietowski JC, Raj DS, Amdur R, Yamamoto J, Mori M, Sugiyama N, Inaguma D, Youssef DM, Alshal AA, Elbehidy RM, Bolignano D, Palmer S, Navaneethan S, Strippoli G, Kim YN, Park K, Gwoo S, Shin HS, Jung YS, Rim H, Rhew HY, Tekce H, Kin Tekce B, Aktas G, Schiepe F, Draz Y, Rakov V, Yilmaz MI, Siriopol D, Saglam M, Kurt YG, Unal H, Eyileten T, Gok M, Cetinkaya H, Oguz Y, Sari S, Vural A, Mititiuc I, Covic A, Kanbay M, Filiopoulos V, Manolios N, Hadjiyannakos D, Arvanitis D, Karatzas I, Vlassopoulos D, Okarska-Napierala M, Ziolkowska H, Pietrzak R, Skrzypczyk P, Jankowska K, Werner B, Roszkowska-Blaim M, Cernaro V, Trifiro G, Lorenzano G, Lucisano S, Buemi M, Santoro D, Krause R, Fuhrmann I, Degenhardt S, Daul AE, Sallee M, Dou L, Cerini C, Poitevin S, Gondouin B, Jourde-Chiche N, Brunet P, Dignat-George F, Burtey S, Massimetti C, Achilli P, Madonna MPP, Muratore MTT, Fabbri GDD, Brescia F, Feriozzi S, Unal HU, Kurt YG, Gok M, Cetinkaya H, Karaman M, Eyileten T, Vural A, Oguz Y, Y lmaz MI, Sugahara M, Sugimoto I, Aoe M, Chikamori M, Honda T, Miura R, Tsuchiya A, Hamada K, Ishizawa K, Saito K, Sakurai Y, Mise N, Gama-Axelsson T, Quiroga B, Axelsson J, Lindholm B, Qureshi AR, Carrero JJ, Pechter U, Raag M, Ots-Rosenberg M, Vande Walle J, Greenbaum LA, Bedrosian CL, Ogawa M, Kincaid JF, Loirat C, Liborio A, Leite TT, Neves FMDO, Torres De Melo CB, Leitao RDA, Cunha L, Filho R, Sheerin N, Loirat C, Greenbaum L, Furman R, Cohen D, Delmas Y, Bedrosian CL, Legendre C, Koibuchi K, Aoki T, Miyagi M, Sakai K, Aikawa A, Pozna Ski P, Sojka M, Kusztal M, Klinger M, Fakhouri F, Bedrosian CL, Ogawa M, Kincaid JF, Loirat C, Heleniak Z, Aleksandrowicz E, Wierblewska E, Kunicka K, Bieniaszewski L, Zdrojewski Z, Rutkowski B. CKD PATHOPHYSIOLOGY AND CLINICAL STUDIES. Nephrol Dial Transplant 2014. [DOI: 10.1093/ndt/gfu148] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
62
|
Chen W, Thielmann I, Gupta S, Subramanian H, Stegner D, van Kruchten R, Dietrich A, Gambaryan S, Heemskerk JWM, Hermanns HM, Nieswandt B, Braun A. Orai1-induced store-operated Ca(2+) entry enhances phospholipase activity and modulates canonical transient receptor potential channel 6 function in murine platelets. J Thromb Haemost 2014; 12:528-39. [PMID: 24520961 DOI: 10.1111/jth.12525] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/08/2013] [Accepted: 01/16/2014] [Indexed: 08/31/2023]
Abstract
BACKGROUND Orai1, the major store-operated Ca(2+) entry (SOCE) channel in platelets, is not only critical for enhancing diverse signaling pathways, but may also regulate receptor-operated Ca(2+) entry (ROCE). Dynamic coupling of the Orai1 signalosome to canonical transient receptor potential channels (TRPCs) has been suggested as an essential step in the activation of SOCE and ROCE. However, the functional significance of the biochemical interaction between Orai and TRPC isoforms remains controversial. OBJECTIVE We aimed to elucidate the role of Orai1 in diacylglycerol (DAG)-mediated ROCE. METHODS Trpc6(-/-) , Orai1(-/-) and Orai1(-/-) /Trpc6(-/-) mice were generated, and their platelets were analyzed. RESULTS Thapsigargin (TG)-induced SOCE was further reduced in Orai1(-/-) /Trpc6(-/-) platelets as compared with Orai1(-/-) platelets, thus revealing that TG-induced signaling pathways can activate TRPC6. Thapsigargin-induced SOCE leads to enhanced phospholipase C and D activity in wild-type platelets. The activity of both enzymes was significantly reduced in Orai1(-/-) platelets upon TG stimulation, whereas receptor-induced phospholipase activity was not affected. Furthermore, TG-induced and glycoprotein VI-mediated thromboxane A2 release was strongly dependent on Orai1-mediated SOCE. CONCLUSION The regulation of TRPC6 activity can occur independently of the physical interaction with Orai1. TRPC6 operates in crosstalk with Orai1 through Orai1-induced DAG production via phospholipase activation. Orai1-induced DAG production and thromboxane release amplify the second phase of Ca(2+) signaling in platelets.
Collapse
Affiliation(s)
- W Chen
- University Hospital and Rudolf Virchow Center for Experimental Biomedicine, University of Würzburg, Würzburg, Germany
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
63
|
Braun A, Richter-Schrag HJ, Fischer A, Hoeppner J. Minimally invasive therapy of perforations at the esophagogastric junction by over-the-scope clipping. Endoscopy 2014; 45 Suppl 2 UCTN:E133-4. [PMID: 23716097 DOI: 10.1055/s-0032-1326449] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/10/2022]
Affiliation(s)
- A Braun
- Surgical Endoscopy, Department of Surgery, University of Freiburg, Germany
| | | | | | | |
Collapse
|
64
|
Dinh QT, Quarcoo D, Braun A, Welte T, Bals R, Fischer A. Neuronale Plastizität in NGF-transgenen Mäusen bei allergischen Atemwegentzündungen. Pneumologie 2014. [DOI: 10.1055/s-0034-1367791] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
65
|
Le DD, Rochlitzer S, Heck S, Bals R, Braun A, Welte T, Dinh QT. Allergische Atemwegsentzündung induziert eine Zunahme von Dendritischen Zellen in den Atemwegsganglien der Maus. Pneumologie 2014. [DOI: 10.1055/s-0034-1367922] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
66
|
Funck U, Le DD, Rochlitzer S, Heck S, Bals R, Braun A, Welte T, Dinh QT. Veränderung von MHC-II positiven Zellen der Atemwegsganglien bei chronischem Hausstaubmilben-Mausmodell und HRV1B Infektion. Pneumologie 2014. [DOI: 10.1055/s-0034-1367785] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
67
|
Paranjpe M, Neuhaus V, Finke JH, Richter C, Gothsch T, Kwade A, Büttgenbach S, Braun A, Müller-Goymann CC. In vitro and ex vivo toxicological testing of sildenafil-loaded solid lipid nanoparticles. Inhal Toxicol 2014; 25:536-43. [PMID: 23905970 DOI: 10.3109/08958378.2013.810315] [Citation(s) in RCA: 32] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
The aim of this study was to investigate the potential cytotoxicity of solid lipid nanoparticles (SLN) loaded with sildenafil. The SLNs were tested as a new drug delivery system (DDS) for the inhalable treatment of pulmonary hypertension in human lungs. Solubility of sildenafil in SLN lipid matrix (30:70 phospholipid:triglyceride) was determined to 1% sildenafil base and 0.1% sildenafil citrate, respectively. Sildenafil-loaded SLN with particle size of approximately 180 nm and monomodal particle size distribution were successfully manufactured using a novel microchannel homogenization method and were stable up to three months. Sildenafil-loaded SLN were then used in in vitro and ex vivo models representing lung and heart tissue. For in vitro models, human alveolar epithelial cell line (A459) and mouse heart endothelium cell line (MHEC5-T) were used. For ex vivo models, rat precision cut lung slices (PCLS) and rat heart slices (PCHS) were used. All the models were treated with plain SLN and sildenafil-loaded SLN in a concentration range of 0-5000 µg/ml of lipid matrix. The toxicity was evaluated in vitro and ex vivo by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Median lethal dose 50% (LD50) values for A549 cells and PCLS were found to be in the range of 1200-1900 µg/ml while for MHEC5-T cells and precision cut heart slices values were found between 1500 and 2800 µg/ml. PCHS showed slightly higher LD50 values in comparison to PCLS. Considering the toxicological aspects, sildenafil-loaded SLN could have potential in the treatment of pulmonary hypertension via inhalation route.
Collapse
Affiliation(s)
- M Paranjpe
- Institut für Pharmazeutische Technologie, TU Braunschweig, Braunschweig, Germany
| | | | | | | | | | | | | | | | | |
Collapse
|
68
|
Wichmann J, Jimenez Delgado SM, Curths C, Becker T, Kaup FJ, Braun A, Sewald K, Knauf S. Frühe Phase der Allergen-induzierten Atemwegsreaktion beim Weißbüschelaffen nach passiver Sensibilisierung von Lungengewebe mit humanem Blutplasma. Pneumologie 2014. [DOI: 10.1055/s-0033-1363101] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
69
|
Curths C, Wichmann J, Becker T, Kaup FJ, Hohlfeld JM, Windt H, Dunker S, Hoymann HG, Braun A, Knauf S. Lung function assessment in the common marmoset (Callithrix jacchus) for the evaluation of translational nonhuman primate models of lung inflammation. Pneumologie 2014. [DOI: 10.1055/s-0033-1363117] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
70
|
Funck U, Le DD, Rochlitzer S, Heck S, Bals R, Braun A, Welte T, Dinh QT. Veränderung von MHC-II positiven Zellen der Atemwegganglien bei chronischem Hausstaubmilben-Mausmodell und HRV1B Infektion. Pneumologie 2014. [DOI: 10.1055/s-0033-1363097] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
71
|
Hansen T, Kopf J, Danov O, Ströbele M, Braun A, Sewald K, Bockhorn H, Fehrenbach H. In vitro and ex vivo toxicity screening for predicting toxicological effects of synthetic carbon black nanoparticles in humans. Pneumologie 2013. [DOI: 10.1055/s-0033-1357065] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
72
|
Curths C, Becker T, Kaup FJ, Schlumbohm C, Sewald K, Hohlfeld JM, Dunker S, Braun A, Knauf S. Ein translationales Tiermodell für das allergische Asthma des Menschen im Weißbüschelaffen (Callithrix jacchus). Pneumologie 2013. [DOI: 10.1055/s-0033-1343971] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
73
|
Seehase S, Switalla S, Neuhaus V, Zöller M, Kaup FJ, Schlumbohm C, Fuchs E, Lauenstein HD, Sewald K, Hohlfeld JM, Braun A, Knauf S. Ein translationales LPS-Modell zur präklinischen Testung anti-inflammatorischer Substanzen im Weißbüschelaffen (Callithrix jacchus). Pneumologie 2013. [DOI: 10.1055/s-0033-1343970] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
74
|
Braun A, Saracbasi E, Grifka J, Kiltz U, Schnittker J, Braun J. SAT0258 Identification of axial spondyloarthritis among patients with chronic back pain in primary care – does determination of HLA B27 improve the performance of clinical assessments of inflammatory back pain? Ann Rheum Dis 2013. [DOI: 10.1136/annrheumdis-2012-eular.3205] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
75
|
Braun A, Gnann H, Saracbasi E, Grifka J, Kiltz U, Letschert K, Braun J. Optimizing the identification of patients with axial spondyloarthritis in primary care--the case for a two-step strategy combining the most relevant clinical items with HLA B27. Rheumatology (Oxford) 2013; 52:1418-24. [DOI: 10.1093/rheumatology/ket115] [Citation(s) in RCA: 37] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
76
|
Patrick D, Smith M, Cleeland C, Fallowfield L, Tombal B, Oudard S, Shore N, Saad F, Marx G, Coleman R, Gómez-Veiga F, Damião R, Zhou Y, Arellano J, Braun A, Qian Y. 99 The impact of bone metastases on pain: Results from a phase III denosumab study in men with nonmetastatic castration-resistant prostate cancer. ACTA ACUST UNITED AC 2013. [DOI: 10.1016/s1569-9056(13)60591-6] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
77
|
Seehase S, Switalla S, Neuhaus V, Zöller M, Kaup FJ, Schlumbohm C, Fuchs E, Lauenstein HD, Sewald K, Hohlfeld JM, Braun A, Knauf S. Ein translationales LPS-Modell zur präklinischen Testung anti-inflammatorischer Substanzen im Weißbüschelaffen (Callitrix jacchus). Pneumologie 2013. [DOI: 10.1055/s-0033-1334803] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
78
|
Curths C, Becker T, Kaup FJ, Schlumbohm C, Sewald K, Hohlfeld JM, Dunker S, Braun A, Knauf S. Ein translationales Tiermodell für das allergische Asthma des Menschen im Weißbüschelaffen (Callithrix jacchus). Pneumologie 2013. [DOI: 10.1055/s-0033-1334802] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
79
|
Switalla S, Knebel J, Ritter D, Dasenbrock C, Krug N, Braun A, Sewald K. Determination of genotoxicity by the Comet assay applied to murine precision-cut lung slices. Toxicol In Vitro 2012; 27:798-803. [PMID: 23274917 DOI: 10.1016/j.tiv.2012.12.015] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/24/2012] [Revised: 12/10/2012] [Accepted: 12/13/2012] [Indexed: 12/30/2022]
Abstract
Precision-cut lung slices (PCLSs) are an organotypic lung model that is widely used in pharmacological, physiological, and toxicological studies. Genotoxicity testing, as a pivotal part of early risk assessment, is currently established in vivo in various organs including lung, brain, or liver, and in vitro in cell lines or primary cells. The aim of the present study was to provide the three-dimensional organ culture PCLS as a new ex vivo model for determination of genotoxicity using the Comet assay. Murine PCLS were exposed to increasing concentrations of ethyl methane sulfonate 'EMS' (0.03-0.4%) and formalin (0.5-5mM). Tissue was subsequently dissociated, and DNA single-strand breaks were quantified using the Comet assay. Number of viable dissociated lung cells was between 4×10(5) and 6.7×10(5)cells/slice. Even treatment with EMS did not induce toxicity compared to untreated tissue control. As expected, DNA single-strand breaks were increased dose-dependently and significantly after exposure to EMS. Here, tail length rose from 24μm to 75μm. In contrast, formalin resulted in a significant induction of DNA cross-links. The effects induced by EMS and formalin demonstrate the usefulness of PCLS as a new ex vivo lung model for genotoxicity testing in the early risk assessment of airborne substances in the future.
Collapse
Affiliation(s)
- S Switalla
- Fraunhofer Institute for Toxicology and Experimental Medicine, Airway Immunology, Nikolai-Fuchs-Str. 1, 30625 Hannover, Germany
| | | | | | | | | | | | | |
Collapse
|
80
|
|
81
|
Fischer A, Bausch D, Baier P, Braun A, Richter-Schrag H. Risk of biodegradable stent-induced hypergranulation causing re-stenosis of a gastric conduit after esophageal resection. Endoscopy 2012; 44 Suppl 2 UCTN:E125-6. [PMID: 22477178 DOI: 10.1055/s-0031-1291693] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Affiliation(s)
- A Fischer
- Department of General and Visceral Surgery, Albert-Ludwigs University of Freiburg, Freiburg, Germany.
| | | | | | | | | |
Collapse
|
82
|
Coleman R, Barrios C, Bell R, Finkelstein D, Iwata H, Martin M, Braun A, Ke C, Maniar T, Goss P. Denosumab Versus Placebo as Adjuvant Treatment for Women With Early-Stage Breast Cancer at High Risk of Disease Recurrence (D-CARE): An in Progress, Phase 3 Clinical Trial. Ann Oncol 2012. [DOI: 10.1016/s0923-7534(20)32883-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022] Open
|
83
|
Braun A, Egger F, Koch K, Briesen H. CFD-Simulation der Strömung einer Herschel-Bulkley-Flüssigkeit in einem Pfropfenstromfermenter. CHEM-ING-TECH 2012. [DOI: 10.1002/cite.201250325] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
84
|
Mayer G, Fitzpatrick G, Frey G, Wigginton H, Woodhead S, Cleeland C, Qian Y, Braun A, Chung K. 14 Addressing Pain in Patients with Solid Tumours and Bone Metastases Receiving the Bone-targeted Therapies Denosumab or Zoledronic Acid. Eur J Oncol Nurs 2012. [DOI: 10.1016/s1462-3889(12)70029-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
85
|
Stopeck A, Richardson G, Siena S, Lipton A, Brown J, Fizazi K, Henry D, Saad F, Ke C, Braun A. AOS13 Denosumab versus zoledronic acid for the prevention of skeletal-related events in patients with bone metastases secondary to solid tumours: An integrated analysis of three phase 3 studies. Eur J Cancer 2012. [DOI: 10.1016/j.ejca.2012.02.030] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
86
|
Stopeck A, Lipton A, Martín M, Body JJ, Paterson A, Steger G, Tonkin K, de Boer R, Fujiwara Y, Yardley D, Jassem J, Takano T, Solal-Céligny P, Fan M, Braun A. AOSOP6 Results from the 2-year open-label extension treatment phase of a pivotal phase 3 study of denosumab in patients with breast cancer and bone metastases previously treated with zoledronic acid or denosumab. Eur J Cancer 2012. [DOI: 10.1016/j.ejca.2012.02.016] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
87
|
Ramanathan G, Gupta S, Thielmann I, Pleines I, Varga-Szabo D, May F, Mannhalter C, Dietrich A, Nieswandt B, Braun A. Defective diacylglycerol-induced Ca2+ entry but normal agonist-induced activation responses in TRPC6-deficient mouse platelets. J Thromb Haemost 2012; 10:419-29. [PMID: 22176814 DOI: 10.1111/j.1538-7836.2011.04596.x] [Citation(s) in RCA: 44] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
BACKGROUND Platelet adhesion, activation and aggregation at sites of vascular injury are essential processes for primary hemostasis. Elevation of the intracellular Ca(2+) concentration is a central event in platelet activation but the underlying mechanisms are not fully understood. Store-operated calcium entry (SOCE) through Orai1 was shown to be the main Ca(2+) influx pathway in murine platelets, but there are additional non-store-operated Ca(2+) (non-SOC) and receptor operated Ca(2+) (ROC) channels expressed in the platelet plasma membrane. OBJECTIVE Canonical transient receptor potential (TRPC) channel 6 is found both in human and murine platelets and has been proposed to mediate diacylglycerol (DAG) activated ROCE but also a role in the regulation of SOCE has been suggested. METHODS To investigate the function of TRPC6 in platelet Ca(2+) signaling and activation, we analyzed platelets from mice deficient in TRPC6 using a wide range of in vitro and in vivo assays. RESULTS In the mutant platelets, DAG activated Ca(2+) influx was found to be abolished. However, this did not significantly affect SOCE or agonist induced Ca(2+) responses. Platelet function in vitro and in vivo was also unaltered in the absence of TRPC6. CONCLUSION Our results indicate that DAG activated ROCE is mediated exclusively by TRPC6 in murine platelets, but this Ca(2+) influx has no major functional relevance for hemostasis and thrombosis. Further, in contrast to previous suggestions, based on studies with human platelets, TRPC6 appears to play an insignificant role in the regulation of SOCE in murine platelets.
Collapse
Affiliation(s)
- G Ramanathan
- Chair of Vascular Medicine, DFG Research Center for Experimental Biomedicine, University Hospital and Rudolf Virchow Center, University of Würzburg, Würzburg, Germany
| | | | | | | | | | | | | | | | | | | |
Collapse
|
88
|
|
89
|
Flak D, Braun A, Mun B, Döbeli M, Graule T, Rekas M. Electronic Structure and Surface Properties of Non-Stoichiometric Fe2O3-δ (α and γ) and Its Application in Gas Sensing. ACTA ACUST UNITED AC 2012. [DOI: 10.1016/j.proeng.2012.09.132] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
90
|
Fallowfield L, Cleeland CS, Body JJ, Stopeck A, von MR, Patrick DL, Clemons M, Tonkin K, Masuda N, Lipton A, De BR, Salvagni S, Tosello OC, Ying W, Braun A, Cong Z. P4-13-01: Pain Severity and Analgesic Use Associated with Skeletal-Related Events in Patients with Advanced Breast Cancer and Bone Metastases. Cancer Res 2011. [DOI: 10.1158/0008-5472.sabcs11-p4-13-01] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Skeletal-related events (SREs), which include pathologic fracture (PF), radiation to bone (RB), surgery to bone (SB), and spinal cord compression (SCC), occur frequently in patients with bone metastases and can lead to debilitating clinical consequences such as functional impairment and bone pain. Denosumab (XGEVA®) is a fully human monoclonal antibody against RANKL, shown to be superior to zoledronic acid (ZA; Zometa®) for the prevention of SREs in patients with solid tumors. Denosumab also delayed the onset of moderate or severe pain compared with ZA. The pain severity and analgesic use associated with each type of SRE were assessed in patients with advanced breast cancer and bone metastases.
Methods: Eligible patients received denosumab 120 mg SC or ZA 4 mg (adjusted for renal function) IV every 4 weeks in a randomized, multinational, double-blind, double-dummy trial. Patient-reported pain was assessed with the Brief Pain Inventory (BPI; 0 no pain to 10 severe pain) at baseline (BL) and at each monthly visit. Opioid and non-opioid analgesic use was recorded and scored using the Analgesic Quantification Algorithm (AQA; 0 no analgesic use to 7 > 600mg oral morphine equivalent/day). Data from the two treatment arms were pooled for this analysis. Pain and analgesic use were evaluated from 6 months prior to and 6 months after the first on-study SRE for each patient. The comparator group included patients without an SRE and was centered at the median time from randomization to first SRE by SRE type, with corresponding 12 month assessments. The proportion of patients with moderate/severe pain (BPI worst pain score > 4) and proportion of patients shifting from no/low analgesic use (AQA ≤ 2) at baseline to strong opioid use (AQA ≥ 3) were reported by month and by SRE type, and are summarized by mean relative change (%) across the time period.
Results: In total, 687 patients with first on-study SRE occurrences (PF=450, RB=201, SCC=16, SB=20) were analyzed. A similar proportion of patients with and without a PF had moderate/severe pain, but a higher proportion of patients with a PF shifted from no/low analgesic use to strong opioid use (mean relative increase 80%). Starting 3 months prior to the event, more patients with RB than those without had moderate/severe pain (27% mean relative increase) and shifted from no/low analgesic use to strong opioid use (mean relative increase 269%). Similar pain and analgesic use patterns were noted for patients with SCC (mean relative increase in pain: 63%; in AQA shift: 913%). More patients with SB than those without had moderate/severe pain in the 6 months leading on to SB (mean relative increase 51%). The difference was attenuated after SB, but during this time a much higher proportion of patients with SB shifted from no/mild opioid use to strong opioid use (mean relative increase 220%).
Discussion: SREs are associated with increased pain severity and analgesic use in patients with advanced breast cancer and bone metastasis. Patterns of pain severity and analgesic use differed by SRE type. Effective treatments to prevent SREs can decrease pain and the need for treatment with opioid analgesics.
Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P4-13-01.
Collapse
Affiliation(s)
- L Fallowfield
- 1Cancer Research UK, University of Sussex, Brighton, United Kingdom; University of Texas, M.D. Anderson Cancer Center, Houston, TX; CHU Brugmann, Université Libre de Bruxelles, Brussels, Belgium; University of Arizona, Arizona Cancer Center, Tucson, AZ; Kantonsspital Graubünden, Chur, Switzerland; University of Washington, Seattle, WA; The Ottawa Hospital Cancer Centre, Ottawa, ON, Canada; Cross Cancer Institute, Edmonton, AB, Canada; Osaka National Hospital, Osaka, Japan; Penn State Milton S. Hershey Medical Center, Hershey, PA; Royal Melbourne Hospital, Melbourne, Australia; Azienda Ospedaliera di Parma, Parma, Italy; Instituto Brasileiro de Controle do Cancer-IBCC, São Paulo, Brazil; Amgen Inc., Thousand Oaks, CA
| | - CS Cleeland
- 1Cancer Research UK, University of Sussex, Brighton, United Kingdom; University of Texas, M.D. Anderson Cancer Center, Houston, TX; CHU Brugmann, Université Libre de Bruxelles, Brussels, Belgium; University of Arizona, Arizona Cancer Center, Tucson, AZ; Kantonsspital Graubünden, Chur, Switzerland; University of Washington, Seattle, WA; The Ottawa Hospital Cancer Centre, Ottawa, ON, Canada; Cross Cancer Institute, Edmonton, AB, Canada; Osaka National Hospital, Osaka, Japan; Penn State Milton S. Hershey Medical Center, Hershey, PA; Royal Melbourne Hospital, Melbourne, Australia; Azienda Ospedaliera di Parma, Parma, Italy; Instituto Brasileiro de Controle do Cancer-IBCC, São Paulo, Brazil; Amgen Inc., Thousand Oaks, CA
| | - J-J Body
- 1Cancer Research UK, University of Sussex, Brighton, United Kingdom; University of Texas, M.D. Anderson Cancer Center, Houston, TX; CHU Brugmann, Université Libre de Bruxelles, Brussels, Belgium; University of Arizona, Arizona Cancer Center, Tucson, AZ; Kantonsspital Graubünden, Chur, Switzerland; University of Washington, Seattle, WA; The Ottawa Hospital Cancer Centre, Ottawa, ON, Canada; Cross Cancer Institute, Edmonton, AB, Canada; Osaka National Hospital, Osaka, Japan; Penn State Milton S. Hershey Medical Center, Hershey, PA; Royal Melbourne Hospital, Melbourne, Australia; Azienda Ospedaliera di Parma, Parma, Italy; Instituto Brasileiro de Controle do Cancer-IBCC, São Paulo, Brazil; Amgen Inc., Thousand Oaks, CA
| | - A Stopeck
- 1Cancer Research UK, University of Sussex, Brighton, United Kingdom; University of Texas, M.D. Anderson Cancer Center, Houston, TX; CHU Brugmann, Université Libre de Bruxelles, Brussels, Belgium; University of Arizona, Arizona Cancer Center, Tucson, AZ; Kantonsspital Graubünden, Chur, Switzerland; University of Washington, Seattle, WA; The Ottawa Hospital Cancer Centre, Ottawa, ON, Canada; Cross Cancer Institute, Edmonton, AB, Canada; Osaka National Hospital, Osaka, Japan; Penn State Milton S. Hershey Medical Center, Hershey, PA; Royal Melbourne Hospital, Melbourne, Australia; Azienda Ospedaliera di Parma, Parma, Italy; Instituto Brasileiro de Controle do Cancer-IBCC, São Paulo, Brazil; Amgen Inc., Thousand Oaks, CA
| | - Moos R von
- 1Cancer Research UK, University of Sussex, Brighton, United Kingdom; University of Texas, M.D. Anderson Cancer Center, Houston, TX; CHU Brugmann, Université Libre de Bruxelles, Brussels, Belgium; University of Arizona, Arizona Cancer Center, Tucson, AZ; Kantonsspital Graubünden, Chur, Switzerland; University of Washington, Seattle, WA; The Ottawa Hospital Cancer Centre, Ottawa, ON, Canada; Cross Cancer Institute, Edmonton, AB, Canada; Osaka National Hospital, Osaka, Japan; Penn State Milton S. Hershey Medical Center, Hershey, PA; Royal Melbourne Hospital, Melbourne, Australia; Azienda Ospedaliera di Parma, Parma, Italy; Instituto Brasileiro de Controle do Cancer-IBCC, São Paulo, Brazil; Amgen Inc., Thousand Oaks, CA
| | - DL Patrick
- 1Cancer Research UK, University of Sussex, Brighton, United Kingdom; University of Texas, M.D. Anderson Cancer Center, Houston, TX; CHU Brugmann, Université Libre de Bruxelles, Brussels, Belgium; University of Arizona, Arizona Cancer Center, Tucson, AZ; Kantonsspital Graubünden, Chur, Switzerland; University of Washington, Seattle, WA; The Ottawa Hospital Cancer Centre, Ottawa, ON, Canada; Cross Cancer Institute, Edmonton, AB, Canada; Osaka National Hospital, Osaka, Japan; Penn State Milton S. Hershey Medical Center, Hershey, PA; Royal Melbourne Hospital, Melbourne, Australia; Azienda Ospedaliera di Parma, Parma, Italy; Instituto Brasileiro de Controle do Cancer-IBCC, São Paulo, Brazil; Amgen Inc., Thousand Oaks, CA
| | - M Clemons
- 1Cancer Research UK, University of Sussex, Brighton, United Kingdom; University of Texas, M.D. Anderson Cancer Center, Houston, TX; CHU Brugmann, Université Libre de Bruxelles, Brussels, Belgium; University of Arizona, Arizona Cancer Center, Tucson, AZ; Kantonsspital Graubünden, Chur, Switzerland; University of Washington, Seattle, WA; The Ottawa Hospital Cancer Centre, Ottawa, ON, Canada; Cross Cancer Institute, Edmonton, AB, Canada; Osaka National Hospital, Osaka, Japan; Penn State Milton S. Hershey Medical Center, Hershey, PA; Royal Melbourne Hospital, Melbourne, Australia; Azienda Ospedaliera di Parma, Parma, Italy; Instituto Brasileiro de Controle do Cancer-IBCC, São Paulo, Brazil; Amgen Inc., Thousand Oaks, CA
| | - K Tonkin
- 1Cancer Research UK, University of Sussex, Brighton, United Kingdom; University of Texas, M.D. Anderson Cancer Center, Houston, TX; CHU Brugmann, Université Libre de Bruxelles, Brussels, Belgium; University of Arizona, Arizona Cancer Center, Tucson, AZ; Kantonsspital Graubünden, Chur, Switzerland; University of Washington, Seattle, WA; The Ottawa Hospital Cancer Centre, Ottawa, ON, Canada; Cross Cancer Institute, Edmonton, AB, Canada; Osaka National Hospital, Osaka, Japan; Penn State Milton S. Hershey Medical Center, Hershey, PA; Royal Melbourne Hospital, Melbourne, Australia; Azienda Ospedaliera di Parma, Parma, Italy; Instituto Brasileiro de Controle do Cancer-IBCC, São Paulo, Brazil; Amgen Inc., Thousand Oaks, CA
| | - N Masuda
- 1Cancer Research UK, University of Sussex, Brighton, United Kingdom; University of Texas, M.D. Anderson Cancer Center, Houston, TX; CHU Brugmann, Université Libre de Bruxelles, Brussels, Belgium; University of Arizona, Arizona Cancer Center, Tucson, AZ; Kantonsspital Graubünden, Chur, Switzerland; University of Washington, Seattle, WA; The Ottawa Hospital Cancer Centre, Ottawa, ON, Canada; Cross Cancer Institute, Edmonton, AB, Canada; Osaka National Hospital, Osaka, Japan; Penn State Milton S. Hershey Medical Center, Hershey, PA; Royal Melbourne Hospital, Melbourne, Australia; Azienda Ospedaliera di Parma, Parma, Italy; Instituto Brasileiro de Controle do Cancer-IBCC, São Paulo, Brazil; Amgen Inc., Thousand Oaks, CA
| | - A Lipton
- 1Cancer Research UK, University of Sussex, Brighton, United Kingdom; University of Texas, M.D. Anderson Cancer Center, Houston, TX; CHU Brugmann, Université Libre de Bruxelles, Brussels, Belgium; University of Arizona, Arizona Cancer Center, Tucson, AZ; Kantonsspital Graubünden, Chur, Switzerland; University of Washington, Seattle, WA; The Ottawa Hospital Cancer Centre, Ottawa, ON, Canada; Cross Cancer Institute, Edmonton, AB, Canada; Osaka National Hospital, Osaka, Japan; Penn State Milton S. Hershey Medical Center, Hershey, PA; Royal Melbourne Hospital, Melbourne, Australia; Azienda Ospedaliera di Parma, Parma, Italy; Instituto Brasileiro de Controle do Cancer-IBCC, São Paulo, Brazil; Amgen Inc., Thousand Oaks, CA
| | - Boer R De
- 1Cancer Research UK, University of Sussex, Brighton, United Kingdom; University of Texas, M.D. Anderson Cancer Center, Houston, TX; CHU Brugmann, Université Libre de Bruxelles, Brussels, Belgium; University of Arizona, Arizona Cancer Center, Tucson, AZ; Kantonsspital Graubünden, Chur, Switzerland; University of Washington, Seattle, WA; The Ottawa Hospital Cancer Centre, Ottawa, ON, Canada; Cross Cancer Institute, Edmonton, AB, Canada; Osaka National Hospital, Osaka, Japan; Penn State Milton S. Hershey Medical Center, Hershey, PA; Royal Melbourne Hospital, Melbourne, Australia; Azienda Ospedaliera di Parma, Parma, Italy; Instituto Brasileiro de Controle do Cancer-IBCC, São Paulo, Brazil; Amgen Inc., Thousand Oaks, CA
| | - S Salvagni
- 1Cancer Research UK, University of Sussex, Brighton, United Kingdom; University of Texas, M.D. Anderson Cancer Center, Houston, TX; CHU Brugmann, Université Libre de Bruxelles, Brussels, Belgium; University of Arizona, Arizona Cancer Center, Tucson, AZ; Kantonsspital Graubünden, Chur, Switzerland; University of Washington, Seattle, WA; The Ottawa Hospital Cancer Centre, Ottawa, ON, Canada; Cross Cancer Institute, Edmonton, AB, Canada; Osaka National Hospital, Osaka, Japan; Penn State Milton S. Hershey Medical Center, Hershey, PA; Royal Melbourne Hospital, Melbourne, Australia; Azienda Ospedaliera di Parma, Parma, Italy; Instituto Brasileiro de Controle do Cancer-IBCC, São Paulo, Brazil; Amgen Inc., Thousand Oaks, CA
| | - Oliveira C Tosello
- 1Cancer Research UK, University of Sussex, Brighton, United Kingdom; University of Texas, M.D. Anderson Cancer Center, Houston, TX; CHU Brugmann, Université Libre de Bruxelles, Brussels, Belgium; University of Arizona, Arizona Cancer Center, Tucson, AZ; Kantonsspital Graubünden, Chur, Switzerland; University of Washington, Seattle, WA; The Ottawa Hospital Cancer Centre, Ottawa, ON, Canada; Cross Cancer Institute, Edmonton, AB, Canada; Osaka National Hospital, Osaka, Japan; Penn State Milton S. Hershey Medical Center, Hershey, PA; Royal Melbourne Hospital, Melbourne, Australia; Azienda Ospedaliera di Parma, Parma, Italy; Instituto Brasileiro de Controle do Cancer-IBCC, São Paulo, Brazil; Amgen Inc., Thousand Oaks, CA
| | - W Ying
- 1Cancer Research UK, University of Sussex, Brighton, United Kingdom; University of Texas, M.D. Anderson Cancer Center, Houston, TX; CHU Brugmann, Université Libre de Bruxelles, Brussels, Belgium; University of Arizona, Arizona Cancer Center, Tucson, AZ; Kantonsspital Graubünden, Chur, Switzerland; University of Washington, Seattle, WA; The Ottawa Hospital Cancer Centre, Ottawa, ON, Canada; Cross Cancer Institute, Edmonton, AB, Canada; Osaka National Hospital, Osaka, Japan; Penn State Milton S. Hershey Medical Center, Hershey, PA; Royal Melbourne Hospital, Melbourne, Australia; Azienda Ospedaliera di Parma, Parma, Italy; Instituto Brasileiro de Controle do Cancer-IBCC, São Paulo, Brazil; Amgen Inc., Thousand Oaks, CA
| | - A Braun
- 1Cancer Research UK, University of Sussex, Brighton, United Kingdom; University of Texas, M.D. Anderson Cancer Center, Houston, TX; CHU Brugmann, Université Libre de Bruxelles, Brussels, Belgium; University of Arizona, Arizona Cancer Center, Tucson, AZ; Kantonsspital Graubünden, Chur, Switzerland; University of Washington, Seattle, WA; The Ottawa Hospital Cancer Centre, Ottawa, ON, Canada; Cross Cancer Institute, Edmonton, AB, Canada; Osaka National Hospital, Osaka, Japan; Penn State Milton S. Hershey Medical Center, Hershey, PA; Royal Melbourne Hospital, Melbourne, Australia; Azienda Ospedaliera di Parma, Parma, Italy; Instituto Brasileiro de Controle do Cancer-IBCC, São Paulo, Brazil; Amgen Inc., Thousand Oaks, CA
| | - Z Cong
- 1Cancer Research UK, University of Sussex, Brighton, United Kingdom; University of Texas, M.D. Anderson Cancer Center, Houston, TX; CHU Brugmann, Université Libre de Bruxelles, Brussels, Belgium; University of Arizona, Arizona Cancer Center, Tucson, AZ; Kantonsspital Graubünden, Chur, Switzerland; University of Washington, Seattle, WA; The Ottawa Hospital Cancer Centre, Ottawa, ON, Canada; Cross Cancer Institute, Edmonton, AB, Canada; Osaka National Hospital, Osaka, Japan; Penn State Milton S. Hershey Medical Center, Hershey, PA; Royal Melbourne Hospital, Melbourne, Australia; Azienda Ospedaliera di Parma, Parma, Italy; Instituto Brasileiro de Controle do Cancer-IBCC, São Paulo, Brazil; Amgen Inc., Thousand Oaks, CA
| |
Collapse
|
91
|
Goss PE, Barrios CH, Bell R, Finkelstein D, Iwata H, Martin M, Braun A, Ke C, Maniar T, Braun S, Dansey R, Coleman RE. OT1-01-03: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Multicenter Study Comparing Denosumab with Placebo as Adjuvant Treatment for Women with Early-Stage Breast Cancer Who Are at High Risk of Disease Recurrence (D-CARE). Cancer Res 2011. [DOI: 10.1158/0008-5472.sabcs11-ot1-01-03] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background
Bone is a common site of distant recurrence in women with early-stage breast cancer. Cancer cells are thought to stimulate osteoclast-mediated bone resorption, which releases growth factors and cytokines that promote tumor growth. RANK Ligand (RANKL) is the key mediator of osteoclast-induced bone destruction. In preclinical studies, RANKL inhibition reduced the incidence of bone and lung metastases, suppressed tumor progression, and prolonged survival of tumor-bearing mice. Effects were additive with hormonal, chemotherapy, or targeted therapies. Denosumab is a fully human monoclonal antibody against RANKL, approved in the U.S. for the prevention of skeletal-related events in patients with bone metastases from solid tumors. In patients with castrate-resistant prostate cancer, denosumab significantly improved bone metastasis-free survival (BMFS) compared to placebo. The D-CARE trial evaluates BMFS effects of denosumab in women with stage II or III breast cancer.
Methods: Women with node-positive or locally advanced (T3 or T4) disease, and known hormone and HER-2 receptor status are eligible. Standard-of-care adjuvant or neoadjuvant chemo-, endocrine, or HER-2 targeted therapy, alone or in combination must be planned with curative intent. Women with a prior history of breast cancer (other than ductal carcinoma in situ [DCIS] or lobular carcinoma in situ [LCIS]) or distant metastasis, oral bisphosphonate (BP) use within 1 year or any intravenous BP use are excluded. Patients are randomized 1:1 to receive denosumab 120 mg or placebo subcutaneously monthly for 6 mos, then every 3 mos, for a total of 5 yrs treatment. All patients receive vitamin D (≥ 400 IU) and calcium (≥ 500 mg) supplements. Primary endpoint of this event-driven trial is BMFS. Secondary endpoints include disease-free (DFS) and overall survival. The study is powered for both, BMFS and DFS. Safety, quality of life assessments and biomarkers are additional endpoints. The trial, sponsored by Amgen Inc. and registered with the ClinicalTrials.gov identifier NCT01077154 began enrolling patients in June 2010. PG and DF are supported in part by the Avon Foundation, NY.
Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr OT1-01-03.
Collapse
Affiliation(s)
- PE Goss
- 1Massachusetts General Hospital Cancer Center, Boston, MA; PUCRS School of Medicine, Porto Alegre RS, Brazil; Barwon Health, Geelong, Victoria, Australia; Aichi Cancer Center Hospital, Nagoya, Japan; Hospital Gregorio Maranon, Madrid, Spain; Amgen Inc, Thousand Oaks, CA; Amgen (Europe) GmbH, Zug, Switzerland; University of Sheffield, Sheffield, United Kingdom
| | - CH Barrios
- 1Massachusetts General Hospital Cancer Center, Boston, MA; PUCRS School of Medicine, Porto Alegre RS, Brazil; Barwon Health, Geelong, Victoria, Australia; Aichi Cancer Center Hospital, Nagoya, Japan; Hospital Gregorio Maranon, Madrid, Spain; Amgen Inc, Thousand Oaks, CA; Amgen (Europe) GmbH, Zug, Switzerland; University of Sheffield, Sheffield, United Kingdom
| | - R Bell
- 1Massachusetts General Hospital Cancer Center, Boston, MA; PUCRS School of Medicine, Porto Alegre RS, Brazil; Barwon Health, Geelong, Victoria, Australia; Aichi Cancer Center Hospital, Nagoya, Japan; Hospital Gregorio Maranon, Madrid, Spain; Amgen Inc, Thousand Oaks, CA; Amgen (Europe) GmbH, Zug, Switzerland; University of Sheffield, Sheffield, United Kingdom
| | - D Finkelstein
- 1Massachusetts General Hospital Cancer Center, Boston, MA; PUCRS School of Medicine, Porto Alegre RS, Brazil; Barwon Health, Geelong, Victoria, Australia; Aichi Cancer Center Hospital, Nagoya, Japan; Hospital Gregorio Maranon, Madrid, Spain; Amgen Inc, Thousand Oaks, CA; Amgen (Europe) GmbH, Zug, Switzerland; University of Sheffield, Sheffield, United Kingdom
| | - H Iwata
- 1Massachusetts General Hospital Cancer Center, Boston, MA; PUCRS School of Medicine, Porto Alegre RS, Brazil; Barwon Health, Geelong, Victoria, Australia; Aichi Cancer Center Hospital, Nagoya, Japan; Hospital Gregorio Maranon, Madrid, Spain; Amgen Inc, Thousand Oaks, CA; Amgen (Europe) GmbH, Zug, Switzerland; University of Sheffield, Sheffield, United Kingdom
| | - M Martin
- 1Massachusetts General Hospital Cancer Center, Boston, MA; PUCRS School of Medicine, Porto Alegre RS, Brazil; Barwon Health, Geelong, Victoria, Australia; Aichi Cancer Center Hospital, Nagoya, Japan; Hospital Gregorio Maranon, Madrid, Spain; Amgen Inc, Thousand Oaks, CA; Amgen (Europe) GmbH, Zug, Switzerland; University of Sheffield, Sheffield, United Kingdom
| | - A Braun
- 1Massachusetts General Hospital Cancer Center, Boston, MA; PUCRS School of Medicine, Porto Alegre RS, Brazil; Barwon Health, Geelong, Victoria, Australia; Aichi Cancer Center Hospital, Nagoya, Japan; Hospital Gregorio Maranon, Madrid, Spain; Amgen Inc, Thousand Oaks, CA; Amgen (Europe) GmbH, Zug, Switzerland; University of Sheffield, Sheffield, United Kingdom
| | - C Ke
- 1Massachusetts General Hospital Cancer Center, Boston, MA; PUCRS School of Medicine, Porto Alegre RS, Brazil; Barwon Health, Geelong, Victoria, Australia; Aichi Cancer Center Hospital, Nagoya, Japan; Hospital Gregorio Maranon, Madrid, Spain; Amgen Inc, Thousand Oaks, CA; Amgen (Europe) GmbH, Zug, Switzerland; University of Sheffield, Sheffield, United Kingdom
| | - T Maniar
- 1Massachusetts General Hospital Cancer Center, Boston, MA; PUCRS School of Medicine, Porto Alegre RS, Brazil; Barwon Health, Geelong, Victoria, Australia; Aichi Cancer Center Hospital, Nagoya, Japan; Hospital Gregorio Maranon, Madrid, Spain; Amgen Inc, Thousand Oaks, CA; Amgen (Europe) GmbH, Zug, Switzerland; University of Sheffield, Sheffield, United Kingdom
| | - S Braun
- 1Massachusetts General Hospital Cancer Center, Boston, MA; PUCRS School of Medicine, Porto Alegre RS, Brazil; Barwon Health, Geelong, Victoria, Australia; Aichi Cancer Center Hospital, Nagoya, Japan; Hospital Gregorio Maranon, Madrid, Spain; Amgen Inc, Thousand Oaks, CA; Amgen (Europe) GmbH, Zug, Switzerland; University of Sheffield, Sheffield, United Kingdom
| | - R Dansey
- 1Massachusetts General Hospital Cancer Center, Boston, MA; PUCRS School of Medicine, Porto Alegre RS, Brazil; Barwon Health, Geelong, Victoria, Australia; Aichi Cancer Center Hospital, Nagoya, Japan; Hospital Gregorio Maranon, Madrid, Spain; Amgen Inc, Thousand Oaks, CA; Amgen (Europe) GmbH, Zug, Switzerland; University of Sheffield, Sheffield, United Kingdom
| | - RE Coleman
- 1Massachusetts General Hospital Cancer Center, Boston, MA; PUCRS School of Medicine, Porto Alegre RS, Brazil; Barwon Health, Geelong, Victoria, Australia; Aichi Cancer Center Hospital, Nagoya, Japan; Hospital Gregorio Maranon, Madrid, Spain; Amgen Inc, Thousand Oaks, CA; Amgen (Europe) GmbH, Zug, Switzerland; University of Sheffield, Sheffield, United Kingdom
| |
Collapse
|
92
|
Dinh QT, Quarcoo D, Wu S, Suhling H, Le DD, Schmeck B, Klapp BF, Krug N, Braun A, Welte T, Fischer A. Veränderungen der Atemweginnervation in NGF-transgenen Mäusen in einem Modell für allergische Atemwegentzündung. Pneumologie 2011. [DOI: 10.1055/s-0031-1296104] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
93
|
Haas O, Ludwig C, Bergmann U, Singh R, Braun A, Graule T. X-ray absorption investigation of the valence state and electronic structure of La1−xCaxCoO3−δ in comparison with La1−xSrxCoO3−δ and La1−xSrxFeO3−δ. J SOLID STATE CHEM 2011. [DOI: 10.1016/j.jssc.2011.09.027] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
94
|
Krasteva G, Canning B, Hartmann P, Veres T, Papadakis T, Mühlfeld C, Schliecker K, Braun A, Weihe E, Schutz B, Ibanez-Tallon I, Kotlikoff MI, Kummer W. Cholinerge chemosensorische Bürstenzellen sind Wächterzellen der Atemwege. Pneumologie 2011. [DOI: 10.1055/s-0031-1296122] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
95
|
Le DD, Rochlitzer S, Funck U, Suhling H, Braun A, Welte T, Dinh QT. Vorkommen von Dendritischen Zellen (DC) im Jugulare/Nodose Ganglion im chronischen Hausstaubmilben-Mausmodell für allergische Atemwegsentzündung. Pneumologie 2011. [DOI: 10.1055/s-0031-1296124] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
96
|
Voedisch S, Rochlitzer S, Spies E, Braun A. Airway dendritic cell behaviour is influenced by neuropeptide release from sensory nerves. Pneumologie 2011. [DOI: 10.1055/s-0031-1296155] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
97
|
Seehase S, Lauenstein HD, Zöller M, Kaup FJ, Schlumbohm C, Sewald K, Braun A, Knauf S. Der Weißbüschelaffe als translationales Tiermodell für entzündliche Atemwegserkrankungen des Menschen. Pneumologie 2011. [DOI: 10.1055/s-0031-1296147] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
98
|
Venzin C, Kook P, Jenni S, Wilhelm S, Degen T, Braun A, Rütten M, Glaus TM. Symptomatic treatment of ascites with a peritoneo-vesical automated fluid shunt system in a dog. J Small Anim Pract 2011; 53:126-31. [PMID: 22106956 DOI: 10.1111/j.1748-5827.2011.01147.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
A six-year-old Rottweiler with chronic ascites and moderate panhypoproteinaemia that had been treated with large volume paracentesis over several months duration was diagnosed with a large bi-atrial mass and hepatic fibrosis. For palliative treatment, a peritoneo-vesical automated fluid shunt system with an integrated chargeable battery and an integrated computer to control pump function and to transmit data transcutaneously was implanted by coeliotomy. The pump was left in place for 10 weeks, eliminating the need for further paracentesis during this time. At the end of this period, no ascites was discernible and serum protein concentrations had returned to their respective reference intervals. As a complication, decubitus with skin perforation had developed above the pump. Besides palliative treatment of chronic refractory ascites, this pump may have application in other conditions characterised by chronic cavity effusion or in peritoneal dialysis.
Collapse
Affiliation(s)
- C Venzin
- Clinic of Small Animal Surgery, Vetsuisse Faculty University of Zurich, Zurich, Switzerland
| | | | | | | | | | | | | | | |
Collapse
|
99
|
Simeon D, Bartz J, Hamilton H, Crystal S, Braun A, Ketay S, Hollander E. Oxytocin administration attenuates stress reactivity in borderline personality disorder: a pilot study. Psychoneuroendocrinology 2011; 36:1418-21. [PMID: 21546164 DOI: 10.1016/j.psyneuen.2011.03.013] [Citation(s) in RCA: 98] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/22/2010] [Revised: 03/18/2011] [Accepted: 03/22/2011] [Indexed: 10/18/2022]
Abstract
Oxytocin has known stress-reducing and attachment-enhancing effects. We thus hypothesized that oxytocin would attenuate emotional and hormonal responses to stress in borderline personality disorder (BPD). Fourteen BPD and 13 healthy control (HC) adults received 40 IU intranasal oxytocin or placebo in double-blind randomized order followed by the Trier Social Stress Test. Subjective dysphoria (Profile of Mood Changes) and plasma cortisol levels were measured. Childhood trauma history, attachment style, and self-esteem were also rated. A significant "Group × Drug × Time" interaction effect for dysphoria (p=.04) reflected a proportionately greater attenuation of stress-induced dysphoria in the BPD group after oxytocin administration. Additionally, a marginally significant "Group × Drug" interaction effect for cortisol (p=.10) reflected a tendency toward greater attenuation of the stress-induced cortisol surge in the BPD group after oxytocin administration. In the combined sample, the oxytocin-placebo difference in the emotional stress reactivity was significantly predicted by childhood trauma alone (p=.037) and combined with self-esteem (p=.030), whereas the oxytocin-placebo difference in cortisol stress reactivity was predicted only by insecure attachment (p=.013). Results suggest that oxytocin may have a beneficial impact on emotional regulation in BPD, which merits further investigation and could have important treatment implications.
Collapse
Affiliation(s)
- D Simeon
- Department of Psychiatry and Behavioral Sciences, Albert Einstein College of Medicine & Beth Israel Medical Center, 317 East 17th Street, New York, NY, USA.
| | | | | | | | | | | | | |
Collapse
|
100
|
|